Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-04

Study Completion Date

2018-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Cryoablation for Metastatic Lung Tumors

NCT01957787

Neoplasm Metastasis

COMPLETED NA

Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

NCT04339218

Lung Adenocarcinoma Cryotherapy Effect

RECRUITING PHASE3

Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases

NCT02511678

Pain Neoplasm Metastasis Bone Metastasis of Diverse Origins

COMPLETED NA

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

NCT01543672

Lung Cancer Metastatic Lung Cancer

COMPLETED PHASE1/PHASE2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

NCT04405401

Lung Cancer Metastatic

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ECLIPSE is a treatment, Phase 1 multicenter, prospective, single-arm study with participants serving as their own control. This study is to enroll participants who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 cm. Participants will be followed for 5 years post their cryoablation procedure.

Cryoablation is the process of destroying tissue by the application of extremely cold temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung), Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal), and urology (kidney).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All participants received the same treatment.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cryoablation

Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.

Group Type OTHER

Cryoablation

Intervention Type DEVICE

Application of extremely cold temperatures to the identified tumor(s).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cryoablation

Application of extremely cold temperatures to the identified tumor(s).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Visual-ICE® Cryoablation System PresIce® Cryoablation System SeedNet® Cryoablation System IceRod® Cryoablation Needles IceRod® PLUS Cryoablation Needles IceSphere™ Cryoablation Needles IceSeed™ Cryoablation Needles IceEDGE™ 2.4 Cryoablation Needles

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be at least 18 years old.
* Participant has signed a written informed consent.
* Participant presents with Stage 4 pulmonary metastatic disease with metastatic disease previously confirmed by prior biopsy or confirmed on imaging with known primary disease.
* Participant has up to 3 local metastases unilaterally targeted by cryoablation. Maximum of 5 total pulmonary tumors bilaterally.
* Targeted tumor(s) defined as intra pulmonary or pleural with a maximum size of 3.5 cm.
* The target tumor is determined (by CT/MRI) to be in a location where cryoablation is technically achievable based on the proximity of adjacent organs and structures.
* Eastern Cooperative Oncology Group (ECOG) score of 0-2.
* Karnofsky Performance Scale (KPS) score ≥60.
* Platelet count \>50,000/cubed millimeters (mm\^3) within 60 days prior to study treatment.
* International normalized ratio (INR) less than 1.5 within 60 days prior to study treatment.
* Participant has a life expectancy of \>3 months.
* Participant is clinically suitable for cryoablation procedure.

Exclusion Criteria

* Participant's primary cancer is lung cancer.
* Participant is unable to lie flat or has respiratory distress at rest.
* Participant has uncontrolled coagulopathy or bleeding disorders.
* Participant has had chemotherapy with neutropenia to levels as confirmed by absolute neutrophil count (ANC) of less than 1000 that produce increase risk for the cryoablation procedure.
* Participant has a history of an allergic reaction to iodine injections or to shellfish.
* Participant has evidence of active systemic, pulmonary, or pericardial infection.
* Participant has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up.
* Participant is currently participating in other experimental studies that could affect the primary endpoint.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No